Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Cell Source, Inc. as of September 30, 2024 is -4.03 MM.
- The net income for Cell Source, Inc. as of September 30, 2024 is -5.23 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2024-09-30 | -4.03 | -5.23 | |
2024-06-30 | -4.19 | -5.15 | |
2024-03-31 | -3.91 | -4.91 | |
2023-09-30 | -4.39 | -5.61 | |
2023-06-30 | -4.41 | -5.52 | |
2023-03-31 | -4.54 | -5.57 | |
2022-12-31 | -4.18 | -5.17 | |
2022-09-30 | -3.69 | -4.67 | |
2022-06-30 | -3.99 | -5.21 | |
2022-03-31 | -3.95 | -5.24 | |
2021-12-31 | -4.02 | -5.47 | |
2021-09-30 | -4.27 | -5.91 | |
2021-06-30 | -4.12 | -5.42 | |
2021-03-31 | -4.03 | -5.27 | |
2020-12-31 | -3.64 | -4.56 | |
2020-09-30 | -3.35 | -3.86 | |
2020-06-30 | |||
2020-03-31 |
Income Statement: EPS
- The earnings per share basic for Cell Source, Inc. as of September 30, 2024 is -0.16.
- The earnings per share diluted for Cell Source, Inc. as of September 30, 2024 is -0.16.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2024-09-30 | -0.16 | -0.16 |
2024-06-30 | -0.16 | -0.16 |
2024-03-31 | -0.16 | -0.16 |
2023-09-30 | -0.18 | -0.18 |
2023-06-30 | -0.19 | -0.18 |
2023-03-31 | -0.19 | -0.19 |
2022-12-31 | -0.18 | -0.18 |
2022-09-30 | -0.17 | -0.16 |
2022-06-30 | -0.19 | -0.18 |
2022-03-31 | -0.19 | -0.18 |
2021-12-31 | -0.19 | -0.19 |
2021-09-30 | -0.22 | -0.22 |
2021-06-30 | -0.21 | -0.21 |
2021-03-31 | -0.21 | -0.21 |
2020-12-31 | -0.19 | |
2020-09-30 | -0.16 | -0.16 |
2020-06-30 | -0.17 | -0.17 |
2020-03-31 | -0.16 | -0.16 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Cell Source, Inc. as of September 30, 2024 is -2.66 MM.
- The cash from financing activities for Cell Source, Inc. as of September 30, 2024 is 2.68 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2024-09-30 | -2.66 | 2.68 | |
2024-06-30 | -2.30 | 2.37 | |
2024-03-31 | -2.21 | 2.08 | |
2023-09-30 | -2.35 | 2.29 | |
2023-06-30 | -3.16 | 3.17 | |
2023-03-31 | -2.42 | 2.42 | |
2022-12-31 | -3.14 | 3.27 | |
2022-09-30 | -2.87 | 2.34 | |
2022-06-30 | -2.45 | 2.37 | |
2022-03-31 | -3.29 | 3.32 | |
2021-12-31 | -3.38 | 3.23 | |
2021-09-30 | -3.68 | 4.22 | |
2021-06-30 | -3.88 | 3.96 | |
2021-03-31 | -3.27 | 3.36 | |
2020-12-31 | -2.77 | 2.99 | |
2020-09-30 | -2.88 | 2.93 | |
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Cell Source, Inc. as of September 30, 2024 is -0.01.
- The p/book for Cell Source, Inc. as of September 30, 2024 is -0.00.
- The p/tbv for Cell Source, Inc. as of September 30, 2024 is -0.00.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2024-09-30 | -0.01 | -0.00 | -0.00 |
2024-06-30 | -0.01 | ||
2024-03-31 | -4.31 | -1.51 | -1.51 |
2023-09-30 | -4.08 | -1.51 | -1.51 |
2023-06-30 | |||
2023-03-31 | -0.02 | -0.01 | |
2022-12-31 | -0.01 | -0.01 | |
2022-09-30 | |||
2022-06-30 | -3.78 | -2.10 | -2.10 |
2022-03-31 | -3.90 | -2.26 | -2.26 |
2021-12-31 | -7.31 | -4.24 | -4.24 |
2021-09-30 | -7.81 | -4.22 | -4.22 |
2021-06-30 | |||
2021-03-31 | -4.34 | -2.53 | -2.53 |
2020-12-31 | -4.99 | -2.87 | -2.87 |
2020-09-30 | -5.43 | -2.99 | -2.99 |
2020-06-30 | -5.14 | -3.18 | -3.18 |
2020-03-31 | -4.99 | -3.06 | -3.06 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Cell Source, Inc. as of September 30, 2024 is -0.52.
- The ebit (3y)/ev for Cell Source, Inc. as of September 30, 2024 is -0.52.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2024-09-30 | -0.52 | -0.52 |
2024-06-30 | -170.91 | -110.20 |
2024-03-31 | -0.17 | -0.16 |
2023-09-30 | -0.17 | -0.11 |
2023-06-30 | 0.00 | -0.24 |
2023-03-31 | -0.65 | -0.70 |
2022-12-31 | -0.65 | -0.67 |
2022-09-30 | 0.00 | -38.52 |
2022-06-30 | -0.20 | -0.18 |
2022-03-31 | -0.20 | -0.17 |
2021-12-31 | -0.12 | -0.10 |
2021-09-30 | -0.11 | -0.09 |
2021-06-30 | ||
2021-03-31 | -0.18 | -0.14 |
2020-12-31 | -0.17 | -0.14 |
2020-09-30 | -0.16 | -0.14 |
2020-06-30 | -0.17 | -0.13 |
2020-03-31 | -0.17 | -0.14 |
Management Effectiveness
- The roa for Cell Source, Inc. as of September 30, 2024 is -20.75.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2024-09-30 | -20.75 | ||||
2024-06-30 | |||||
2024-03-31 | -13.68 | ||||
2023-09-30 | |||||
2023-06-30 | 0.00 | ||||
2023-03-31 | -16.85 | ||||
2022-12-31 | -5.42 | ||||
2022-09-30 | 0.00 | ||||
2022-06-30 | -17.74 | ||||
2022-03-31 | -18.54 | ||||
2021-12-31 | -13.07 | ||||
2021-09-30 | -28.11 | ||||
2021-06-30 | -65.86 | ||||
2021-03-31 | -40.04 | ||||
2020-12-31 | -39.73 | ||||
2020-09-30 | -49.87 | ||||
2020-06-30 | -50.76 | ||||
2020-03-31 | -65.04 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Identifiers and Descriptors
Central Index Key (CIK) | 1569340 |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |